



## Seer to Present at the Cowen 41st Annual Healthcare Conference

REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating in the upcoming Cowen 41<sup>st</sup> Annual Healthcare Conference.

Seer's management is scheduled to participate in a fireside chat on Wednesday, March 3 at 8:40 a.m. Pacific Time / 11:40 a.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer's website at [investor.seer.bio](http://investor.seer.bio). An archived replay will be available on the company's website following the conference.

### About Seer

Seer™ is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. Seer is developing its Proteograph™ Product Suite, which is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. Seer designed the Proteograph to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution broadly available to life sciences researchers. Seer's Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit [www.seer.bio](http://www.seer.bio).

### Investor Contact

Carrie Mendivil  
[investor@seer.bio](mailto:investor@seer.bio)

### Media Contact

Karen Possemato  
[pr@seer.bio](mailto:pr@seer.bio)